Details for New Drug Application (NDA): 020105
✉ Email this page to a colleague
NDA 020105 describes TRIOSTAT, which is a drug marketed by Endo Operations and is included in one NDA. Additional details are available on the TRIOSTAT profile page.
The generic ingredient in TRIOSTAT is liothyronine sodium. There are four drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.
The generic ingredient in TRIOSTAT is liothyronine sodium. There are four drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.
Summary for 020105
| Tradename: | TRIOSTAT |
| Applicant: | Endo Operations |
| Ingredient: | liothyronine sodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 0.01MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 31, 1991 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
